Works by Usmani, Saad Z.

Results: 111
    1

    Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real‐world data.

    Published in:
    British Journal of Haematology, 2025, v. 206, n. 6, p. 1642, doi. 10.1111/bjh.20050
    By:
    • Biran, Noa;
    • Dhakal, Binod;
    • Niesvizky, Ruben;
    • Lentzsch, Suzanne;
    • Bhutani, Divaya;
    • McKay, John T.;
    • Vesole, David H.;
    • Nooka, Ajay;
    • Paul, Barry;
    • Hari, Parameswaran N.;
    • D'Ambrosi, Silvia;
    • Kuiper, Rowan;
    • van Vliet, Martin;
    • Siegel, David;
    • Usmani, Saad Z.;
    • van Rhee, Frits
    Publication type:
    Article
    2

    Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.

    Published in:
    EJHaem, 2022, v. 3, n. 1, p. 97, doi. 10.1002/jha2.312
    By:
    • Martin, Thomas;
    • Krishnan, Amrita;
    • Yong, Kwee;
    • Weisel, Katja;
    • Mehra, Maneesha;
    • Nair, Sandhya;
    • Qi, Keqin;
    • Londhe, Anil;
    • Diels, Joris;
    • Crivera, Concetta;
    • Jackson, Carolyn C.;
    • Olyslager, Yunsi;
    • Vogel, Martin;
    • Schecter, Jordan M.;
    • Banerjee, Arnob;
    • Valluri, Satish;
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Jagannath, Sundar
    Publication type:
    Article
    3

    Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.

    Published in:
    EJHaem, 2021, v. 2, n. 3, p. 375, doi. 10.1002/jha2.209
    By:
    • Biran, Noa;
    • Dhakal, Binod;
    • Lentzsch, Suzanne;
    • Siegel, David;
    • Usmani, Saad Z.;
    • Rossi, Adriana;
    • Rosenbaum, Cara;
    • Bhutani, Divaya;
    • Vesole, David H.;
    • Rodriguez, Cesar;
    • Nooka, Ajay K.;
    • van Rhee, Frits;
    • Stork‐Sloots, Lisette;
    • de Snoo, Femke;
    • Bhattacharyya, Pritish K.;
    • Dash, Durga Prasad;
    • Zümrütçü, Sena;
    • van Vliet, Martin H.;
    • Hari, Parameswaran;
    • Niesvizky, Ruben
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01048-0
    By:
    • Costa, Bruno Almeida;
    • Flynn, Jessica;
    • Nishimura, Noriko;
    • Devlin, Sean M.;
    • Farzana, Tasmin;
    • Rajeeve, Sridevi;
    • Chung, David J.;
    • Landau, Heather J.;
    • Lahoud, Oscar B.;
    • Scordo, Michael;
    • Shah, Gunjan L.;
    • Hassoun, Hani;
    • Maclachlan, Kylee;
    • Hultcrantz, Malin;
    • Korde, Neha;
    • Lesokhin, Alexander M.;
    • Shah, Urvi A.;
    • Tan, Carlyn R.;
    • Giralt, Sergio A.;
    • Usmani, Saad Z.
    Publication type:
    Article
    13
    14
    15

    Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00882-y
    By:
    • Tan, Carlyn Rose;
    • Derkach, Andriy;
    • Nemirovsky, David;
    • Ciardiello, Amanda;
    • Diamond, Benjamin;
    • Hultcrantz, Malin;
    • Hassoun, Hani;
    • Mailankody, Sham;
    • Shah, Urvi;
    • Maclachlan, Kylee;
    • Patel, Dhwani;
    • Lahoud, Oscar B.;
    • Landau, Heather J.;
    • Chung, David J.;
    • Shah, Gunjan L.;
    • Scordo, Michael;
    • Giralt, Sergio A.;
    • Lesokhin, Alexander;
    • Usmani, Saad Z.;
    • Landgren, Ola
    Publication type:
    Article
    16
    17

    Extreme body mass index and survival in newly diagnosed multiple myeloma patients.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00782-7
    By:
    • Shah, Urvi A.;
    • Whiting, Karissa;
    • Devlin, Sean;
    • Ershler, Rachel;
    • Kanapuru, Bindu;
    • Lee, David J.;
    • Tahri, Sabrin;
    • Gwise, Thomas;
    • Rustad, Even H.;
    • Mailankody, Sham;
    • Lesokhin, Alexander M.;
    • Kazandjian, Dickran;
    • Maura, Francesco;
    • Auclair, Daniel;
    • Birmann, Brenda M.;
    • Usmani, Saad Z.;
    • Gormley, Nicole;
    • Marinac, Catherine R.;
    • Landgren, Ola
    Publication type:
    Article
    18
    19
    20
    21

    Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 2, p. 1, doi. 10.1038/s41408-021-00432-4
    By:
    • Terpos, Evangelos;
    • Mikhael, Joseph;
    • Hajek, Roman;
    • Chari, Ajai;
    • Zweegman, Sonja;
    • Lee, Hans C.;
    • Mateos, María-Victoria;
    • Larocca, Alessandra;
    • Ramasamy, Karthik;
    • Kaiser, Martin;
    • Cook, Gordon;
    • Weisel, Katja C.;
    • Costello, Caitlin L.;
    • Elliott, Jennifer;
    • Palumbo, Antonio;
    • Usmani, Saad Z.
    Publication type:
    Article
    22

    P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC‐1 STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970428.90600.b0
    By:
    • Bhutani, Manisha;
    • Garfall, Alfred;
    • Uttervall, Katarina;
    • Usmani, Saad Z;
    • Karlin, Lionel;
    • Benboubker, Lotfi;
    • Nahi, Hareth;
    • San Miguel, Jesús;
    • Trancucci, Danielle;
    • Qi, Keqin;
    • Stephenson, Tara;
    • Perales‐Puchalt, Alfredo;
    • Chastain, Katherine;
    • Chari, Ajai
    Publication type:
    Article
    23

    P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C.

    Published in:
    2023
    By:
    • Alsina, Melissa;
    • Dhodapkar, Madhav;
    • Berdeja, Jesus;
    • Patel, Krina;
    • Richard, Shambavi;
    • Vij, Ravi;
    • Leleu, Xavier;
    • Egan, Daniel;
    • Leif Bergsagel, P.;
    • Ran, Reshef;
    • Usmani, Saad Z;
    • Truppel-Hartmann, Anna;
    • Basudhar, Debashree;
    • Thompson, Ethan;
    • Zheng, Xirong;
    • Zhong, Xiaobo;
    • Greggio, Chiara;
    • Popa Mckiver, Mihaela;
    • Carrasco Alfonso, Marlene;
    • Siegel, David
    Publication type:
    Abstract
    24

    P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9.

    Published in:
    2023
    By:
    • Usmani, Saad Z;
    • Mielnik, Michał;
    • Min Byun, Ja;
    • Alonso Alonso, Aránzazu;
    • Abdallah, Al-Ola;
    • Garg, Mamta;
    • Quach, Hang;
    • Min, Chang-Ki;
    • Janowski, Wojciech;
    • Miguel, Enrique Maria Ocio San;
    • Weisel, Katja;
    • Oriol, Albert;
    • Sandhu, Irwindeep;
    • Rodríguez-Otero, Paula;
    • Ramasamy, Karthik;
    • Egger, Jacqueline;
    • Williams, Danaè;
    • MA, Jie;
    • Kaisermann, Morrys;
    • Hus, Marek
    Publication type:
    Abstract
    25

    S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.

    Published in:
    2023
    By:
    • Munshi, Nikhil;
    • Martin, Tom;
    • Usmani, Saad Z;
    • Berdeja, Jesus;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D;
    • Deol, Abhinav;
    • Htut, Myo;
    • Lesokhin, Alexander;
    • Lin, Yi;
    • O'donnell, Elizabeth;
    • Jackson, Carolyn C;
    • Yeh, Tzu-Min;
    • Banerjee, Arnob;
    • Zudaire, Enrique;
    • Madduri, Deepu;
    • Delcorral, Christopher;
    • Pacaud, Lida;
    • Jagannath, Sundar
    Publication type:
    Abstract
    26
    27
    28

    Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 2, p. 468, doi. 10.1080/10428194.2022.2148221
    By:
    • Nahi, Hareth;
    • Usmani, Saad Z.;
    • Mateos, Maria-Victoria;
    • van de Donk, Niels W. C. J.;
    • Oriol, Albert;
    • Plesner, Torben;
    • Bandyopadhyay, Nibedita;
    • Hellemans, Peter;
    • Tromp, Brenda;
    • Nnane, Ivo;
    • Zemlickis, Donna;
    • Chari, Ajai;
    • Moreau, Philippe
    Publication type:
    Article
    29

    A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 14, p. 3488, doi. 10.1080/10428194.2022.2131417
    By:
    • Nath, Karthik;
    • Shekarkhand, Tala;
    • Salcedo, Meghan;
    • Derkach, Andriy;
    • Rueda, Siobhan;
    • Chansakul, Aisara;
    • Hulcrantz, Malin;
    • Korde, Neha;
    • Shah, Urvi A.;
    • Tan, Carlyn;
    • Chung, David J.;
    • Lahoud, Oscar B.;
    • Hassoun, Hani;
    • Lesokhin, Alexander M.;
    • Landau, Heather J.;
    • Shah, Gunjan;
    • Scordo, Michael;
    • Giralt, Sergio A.;
    • Usmani, Saad Z.;
    • Roshal, Mikhail
    Publication type:
    Article
    30
    31
    32
    33

    Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 11, p. 2588, doi. 10.1080/10428194.2018.1443337
    By:
    • Chari, Ajai;
    • Larson, Sarah;
    • Holkova, Beata;
    • Cornell, Robert F.;
    • Gasparetto, Cristina;
    • Karanes, Chatchada;
    • Matous, Jeffrey V.;
    • Niesvizky, Ruben;
    • Valent, Jason;
    • Lunning, Matthew;
    • Usmani, Saad Z.;
    • Anderson, Larry D.;
    • Chang, Lipo;
    • Lee, Yihua;
    • Pak, Yvonne;
    • Salman, Zeena;
    • Graef, Thorsten;
    • Bilotti, Elizabeth;
    • Chhabra, Saurabh
    Publication type:
    Article
    34

    Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

    Published in:
    Leukemia & Lymphoma, 2016, v. 57, n. 5, p. 1114, doi. 10.3109/10428194.2015.1090572
    By:
    • Bhutani, Manisha;
    • Turkbey, Baris;
    • Tan, Esther;
    • Korde, Neha;
    • Kwok, Mary;
    • Manasanch, Elisabet E.;
    • Tageja, Nishant;
    • Mailankody, Sham;
    • Roschewski, Mark;
    • Mulquin, Marcia;
    • Carpenter, Ashley;
    • Lamping, Elizabeth;
    • Minter, Alex R.;
    • Weiss, Brendan M.;
    • Mena, Esther;
    • Lindenberg, Liza;
    • Calvo, Katherine R.;
    • Maric, Irina;
    • Usmani, Saad Z.;
    • Choyke, Peter L.
    Publication type:
    Article
    35
    36
    37

    Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

    Published in:
    Current Medical Research & Opinion, 2023, v. 39, n. 1, p. 81, doi. 10.1080/03007995.2022.2139052
    By:
    • Martin, Tom;
    • Usmani, Saad Z.;
    • Schecter, Jordan M.;
    • Roccia, Tito;
    • Jackson, Carolyn C.;
    • Deraedt, William;
    • Yeh, Tzu-min;
    • Banerjee, Arnob;
    • Pacaud, Lida;
    • Garrett, Ashraf;
    • Bartlett, Meaghan;
    • Haltner, Anja;
    • Van Sanden, Suzy;
    • Diels, Joris;
    • Valluri, Satish;
    • Samjoo, Imtiaz A.
    Publication type:
    Article
    38

    Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.

    Published in:
    Current Medical Research & Opinion, 2022, v. 38, n. 10, p. 1759, doi. 10.1080/03007995.2022.2100651
    By:
    • Costa, Luciano J.;
    • Hari, Parameswaran;
    • Berdeja, Jesus G.;
    • De Stefano, Valerio;
    • Gay, Francesca;
    • Hooper, Becky;
    • Bartlett, Meaghan;
    • Haltner, Anja;
    • Rosta, Emily;
    • Kumar, Shaji;
    • Martin, Thomas;
    • Mateos, Maria-Victoria;
    • Moreau, Philippe;
    • Usmani, Saad Z.;
    • Olyslager, Yunsi;
    • Schecter, Jordan M.;
    • Roccia, Tito;
    • Garrett, Ashraf;
    • Lee, Sam;
    • Nesheiwat, Tonia
    Publication type:
    Article
    39

    Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

    Published in:
    Current Medical Research & Opinion, 2021, v. 37, n. 10, p. 1779, doi. 10.1080/03007995.2021.1953456
    By:
    • Martin, Tom;
    • Usmani, Saad Z.;
    • Schecter, Jordan M.;
    • Vogel, Martin;
    • Jackson, Carolyn C.;
    • Deraedt, William;
    • Tian, Hong;
    • Yeh, Tzu-min;
    • Banerjee, Arnob;
    • Pacaud, Lida;
    • Garrett, Ashraf;
    • Haltner, Anja;
    • Cameron, Chris;
    • Van Sanden, Suzy;
    • Diels, Joris;
    • Valluri, Satish;
    • Samjoo, Imtiaz A.
    Publication type:
    Article
    40

    Therapy-Related Myeloid Malignancies in Myeloma.

    Published in:
    Mediterranean Journal of Hematology & Infectious Diseases, 2011, v. 3, n. 1, p. 1, doi. 10.4084/MJHID.2011.047
    By:
    • Papanikolaou, Xenofon;
    • Barlogie, Bart;
    • Usmani, Saad Z.
    Publication type:
    Article
    41

    High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

    Published in:
    Cytometry. Part A, 2019, v. 95, n. 3, p. 279, doi. 10.1002/cyto.a.23693
    By:
    • Adams, Homer C.;
    • Stevenaert, Frederik;
    • Krejcik, Jakub;
    • Van der Borght, Koen;
    • Smets, Tina;
    • Bald, Jaime;
    • Abraham, Yann;
    • Ceulemans, Hugo;
    • Chiu, Christopher;
    • Vanhoof, Greet;
    • Usmani, Saad Z.;
    • Plesner, Torben;
    • Lonial, Sagar;
    • Nijhof, Inger;
    • Lokhorst, Henk M.;
    • Mutis, Tuna;
    • Donk, Niels W.C.J.;
    • Sasser, Amy Kate;
    • Casneuf, Tineke
    Publication type:
    Article
    42
    43

    Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 2, p. 619, doi. 10.1007/s00432-020-03365-w
    By:
    • Usmani, Saad Z.;
    • Mateos, Maria-Victoria;
    • Hungria, Vania;
    • Iida, Shinsuke;
    • Bahlis, Nizar J.;
    • Nahi, Hareth;
    • Magen, Hila;
    • Cavo, Michele;
    • Hulin, Cyrille;
    • White, Darrell;
    • De Stefano, Valerio;
    • Fastenau, John;
    • Slavcev, Mary;
    • Heuck, Christoph;
    • Qin, Xiang;
    • Pei, Huiling;
    • Masterson, Tara;
    • Lantz, Kristen;
    • Gries, Katharine S.
    Publication type:
    Article
    44
    45

    Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.

    Published in:
    Annals of Hematology, 2021, v. 100, n. 4, p. 1065, doi. 10.1007/s00277-021-04405-2
    By:
    • Iida, Shinsuke;
    • Ishikawa, Takayuki;
    • Min, Chang Ki;
    • Kim, Kihyun;
    • Yeh, Su Peng;
    • Usmani, Saad Z.;
    • Mateos, Maria-Victoria;
    • Nahi, Hareth;
    • Heuck, Christoph;
    • Qin, Xiang;
    • Parasrampuria, Dolly A.;
    • Gries, Katharine S.;
    • Qi, Ming;
    • Bahlis, Nizar;
    • Ito, Shigeki
    Publication type:
    Article
    46
    47
    48
    49
    50